INTRODUCTION
============

Various types of conventional radical surgery (CRS), such as radical hysterectomy, radical trachelectomy, and radical parametrectomy, have shown 5-year survival rates of more than 90%, and remain the standard treatment for patients with early-stage cervical cancer \[[@B1],[@B2]\]. However, CRS is known to cause urinary dysfunctions, such as bladder hypotonia, urinary incontinence, and abnormal sensation, in 12% to 85% of patients \[[@B3],[@B4],[@B5]\]. Furthermore, anorectal dysfunctions, including constipation, have been reported in 5% to 10% of patients after CRS \[[@B6],[@B7]\]. Considerable sexual dysfunctions, including decrease in sexual interest and orgasm, and vaginal dryness, are also noticed after CRS, which compromise sexual activity and result in substantial distress \[[@B8]\].

Urinary, anorectal, and sexual dysfunctions are known to be caused by injury to of the pelvic autonomic nerves during CRS. These nerves play a major role for the neurogenic control of urinary and anorectal functions. Moreover, they supply blood vessels of the female genital tract and thereby affect sexual activity by neurogenically controlling its lubrication or swelling response \[[@B9]\]. Thus, nerve-sparing radical surgery (NSRS) has emerged in the last 30 years for reducing surgery-related dysfunctions without compromising oncologic outcomes \[[@B10]\]. However, the efficacy and safety of NSRS are still controversial in comparison with CRS despite a growing number of studies addressing the issue of NSRS. In particular, major limitations are no consensus on which part of the uterine-supporting ligaments the nerve-sparing technique should be directed to, an unresolved concern about whether NSRS may interfere with radicality necessary for treating cervical cancer, and a debate on the discrepancy in prognosis between CRS and NSRS.

Although three prospective randomized controlled trials (RCTs) and one systematic review with a meta-analysis have been published up to now \[[@B11],[@B12],[@B13],[@B14]\], they are not enough to clarify the efficacy and safety of NSRS in cervical cancer due to small numbers of enrolled patients and non-English literature that hinder extraction of relevant data. Thus, this meta-analysis was performed to compare clinical outcomes, and urinary, anorectal, and sexual dysfunctions between CRS and NSRS in patients with early-stage cervical cancer.

MATERIALS AND METHODS
=====================

1. Search strategy and selection criteria
-----------------------------------------

This meta-analysis was conducted in line with the recommendations from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@B15]\]. For this meta-analysis, we searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library for relevant studies published from January 2000 to February 2014 inclusive using the following terms: \"cervical neoplasm(s)\" or \"cervical cancer\" or \"cervical carcinoma,\" and \"nerve sparing.\"

We included relevant studies that met the following criteria: cervical cancer; comparison of clinical outcomes between CRS and NSRS; and comparison of urinary, anorectal, or sexual dysfunctions between CRS and NSRS. However, review articles, case reports, editorials or letters to the editor, and non-English studies that did not meet the selection criteria were excluded from this meta-analysis.

2. Selection of studies
-----------------------

Two of the authors (HSK and KK) independently evaluated the potential eligibility of all studies retrieved from the database based on the predetermined selection and exclusion criteria, and the third author (CWJ) resolved disagreement between the two authors through consensus conference. A total of 166 studies were identified, and we excluded 27 duplicates and 51 studies, including reviews (n=23), non-English literature (n=13), editorials or letters to the editor (n=9), and case reports (n=6). In addition, we excluded 54 studies due to non-comparative studies (n=41) and non-cervical cancer (n=13). Thirteen studies were also excluded due to data on surgical technique or anatomy only (n=8), and lack of data for comparison (n=5). Finally, two RCTs \[[@B12],[@B13]\], seven prospective cohort \[[@B7],[@B9],[@B16],[@B17],[@B18],[@B19],[@B20]\], and 11 retrospective cohort studies \[[@B10],[@B21],[@B22],[@B23],[@B24],[@B25],[@B26],[@B27],[@B28],[@B29],[@B30]\] were included in this meta-analysis ([Fig. 1](#F1){ref-type="fig"}).

3. Data collection
------------------

Data extraction was performed by two authors (HSK and SBR), and any discrepancies were addressed by a joint reevaluation of the article with the third author (KSH). The following data were independently extracted from each study for this meta-analysis: the first author; period of enrollment; study design; the International Federation of Gynecology and Obstetrics (FIGO) stage; surgical approach; surgical types such as radical hysterectomy, radical trachelectomy, or radical parametrectomy; radicality of surgery; number of patients with cervical cancer who underwent CRS or NSRS; neoadjuvant chemotherapy (NAC); adjustment for potential confounding factors; clinical outcomes, including operative time (minute), blood loss (mL), hospital stay (day), intraoperative or postoperative complications, length of the resected vagina or parametrium (mm), disease-free survival (DFS), and overall survival (OS); urinary dysfunctions, including duration of postoperative catheterization (DPC, day), urinary incontinence and frequency, urinary retention and urgency and dysuria; anorectal dysfunctions including constipation, diarrhea and fecal incontinence; and sexual dysfunctions, including a decrease in sexual interest, dyspareunia, decreases in orgasm and sexual satisfaction, and vaginal dryness.

Since the classification of radical surgeries for cervical cancer has been changed from the Piver-Rutledge system to the Querleu-Morrow system since 2008 \[[@B31],[@B32]\], we considered that types II and III were similar to types B and C, respectively. In particular, NSRS was evaluated by full review of some studies where the Piver-Rutledge system was used due to no subtype for defining NSRS \[[@B7],[@B9],[@B10],[@B12],[@B13],[@B16],[@B17],[@B18],[@B20],[@B21],[@B22],[@B27],[@B28],[@B29],[@B30]\], whereas type C1 was considered to be NSRS in other studies based on the Querleu-Morrow system \[[@B19],[@B23],[@B24],[@B25],[@B26]\].

Bladder injury, bowel perforation, vessel injury, and hemorrhage with estimated blood loss \>1,000 mL were considered to be intraoperative complications \[[@B25],[@B27],[@B28]\]. Postoperative complications included acute renal failure, bleeding from surgical sites, dysesthesia, febrile morbidity, ileus, infection on surgical sites, lymphocele, metabolic complications, pyelonephritis, reoperation, thromboembolism, and ureteral fistula or stenosis \[[@B10],[@B12],[@B18],[@B21],[@B24], [@B27], [@B28], [@B30]\]. DPC was defined as the time to achieve postvoid residual urine of ≤50 \[[@B13],[@B16],[@B18],[@B19],[@B23],[@B25]\] or ≤100 mL \[[@B12],[@B21],[@B24],[@B28],[@B30]\]. Urinary, anorectal, and sexual dysfunctions were evaluated through interviews or self-reports 6 \[[@B19],[@B30]\] or 12 months after surgery \[[@B9],[@B12],[@B20],[@B22],[@B28],[@B29]\].

4. Quality assessment
---------------------

In CRS sacrificing the pelvic autonomic nerves-the hypogastric nerve containing sympathetic nerves, the pelvic splanchnic nerve containing parasympathetic nerves, and the vesical branch of pelvic plexus containing both sympathetic and parasympathetic nerves-are known to be easily injured during dissection of the uterosacral ligament, the parametrium, and the posterior part of the vesicouterine ligament, respectively \[[@B9]\]. Thus, we focused on whether each of the three nerves was preserved by NSRS to assess the quality of individual studies because they used different nerve-sparing techniques. As a result, it was found that the three nerves were preserved in all except one study \[[@B16]\], and only five studies confirmed the success rate of the nerve-sparing technique on at least one side ([Supplementary Table 1](#S5){ref-type="supplementary-material"}) \[[@B17],[@B18],[@B19],[@B22],[@B29]\].

Furthermore, we assessed the quality of individual studies using the Newcastle-Ottawa Scale (NOS) for 18 enrolled cohort studies \[[@B33]\]. The NOS consists of the following three parameters of quality: selection, comparability, and outcome. It assigns a maximum of four points for selection, two points for comparability, and three points for outcome. In this meta-analysis, we considered a study with an NOS score of ≥8 to be a high-quality study because the mean NOS score was 7.6. As a result, 10 studies (55.6%) showed high quality ([Supplementary Table 2](#S6){ref-type="supplementary-material"}).

5. Statistical analyses
-----------------------

Continuous variables were shown as standard difference in means (SDMs) with 95% confidence intervals (CIs), which were calculated from mean, SD or p-value, and sample size in each study. Dichotomous data eligible in each study were demonstrated as an odds ratio (OR) with 95% CIs. Furthermore, we conducted survival analysis using a statistical method describer by Tierney et al. \[[@B34]\]. Heterogeneity was assessed using Higgins I^2^, evaluating the percentage of total variation across studies which was due to heterogeneity rather than chance \[[@B35]\]. Thus, an I^2^ of \>50% was considered to represent substantial heterogeneity, and thereby we used the random effects model using the DerSimonian and Laird method. On the other hand, the fixed effect model using the Mantel-Haenszel method was employed when I^2^ was ≤50% because it meant no heterogeneity.

Funnel plots were represented to identify publication bias, which were scattered plots of SMDs, ORs, or hazard ratios of individual studies on the x axis against the standard error on the y axis. As a result, all funnel plots resembled symmetric inverter funnels, suggesting no publication bias in this meta-analysis. Moreover, we performed Egger\'s test if at least three studies were included for each outcome and thereby found no publication bias (p\>0.05) ([Supplementary Fig. 1](#S1){ref-type="supplementary-material"}). For this meta-analysis, we used SPSS ver. 19.0 (SPSS Inc., Chicago, IL, USA) and Comprehensive Meta-Analysis ver. 2.0 (Biostat Inc., Englewood, NJ, USA). A p-value of \<0.05 was considered to be statistically significant.

RESULTS
=======

[Supplementary Table 3](#S7){ref-type="supplementary-material"} shows the general characteristics of 20 comparative studies that included 2,253 patients with cervical cancer. Among them, 1,130 (50.2%) underwent CRS, while 1,145 (49.8%) received NSRS, and there was no significant difference in the frequency of NAC between CRS and NSRS in all except two studies \[[@B27],[@B30]\]. Furthermore, potential confounding factors, including age, adjuvant treatment, body mass index, FIGO stage, depth of stromal invasion, extent of lymphadenectomy, grade, histology, lymph node metastasis, number of resected lymph nodes, parametrial invasion, positive resection margin, and tumor size were adjusted in most of the studies.

As a result, crude analyses showed that blood loss (SDM, -0.251; 95% CI, -0.391 to -0.110) and hospital stay (SDM, -0.224; 95% CI, -0.400 to -0.047) were less, and intraoperative complications (OR, 0.273; 95% CI, 0.105 to 0.715) were less common in patients treated with NSRS. Moreover, the length of the resected vagina was significantly shorter in NSRS than in CRS (SDM, -0.498; 95% CI, -0.795 to -0.201) ([Fig. 2](#F2){ref-type="fig"}). However, there were no significant differences in operative time, postoperative complications, the length of the resected parametrium, DFS, and OS between the two groups ([Supplementary Fig. 2](#S2){ref-type="supplementary-material"}).

When we performed subgroup analyses for at least three studies to evaluate each outcome according to study design, quality of study, surgical approach, radicality, and adjustment for potential confounding factors, operative time (SDM, 0.948; 95% CI, 0.642 to 1.253) was longer, and intraoperative complications were less common (OR, 0.147; 95% CI, 0.035 to 0.621) in NSRS ([Table 1](#T1){ref-type="table"}), whereas there were no differences in blood loss, hospital stay, and postoperative complications between NSRS and CRS after adjustment for age, body mass index, extent of lymphadenectomy, FIGO stage, and number of resected lymph nodes ([Supplementary Table 4](#S7){ref-type="supplementary-material"}). In terms of survival, DFS and OS were not different between the two treatments ([Table 2](#T2){ref-type="table"}).

In regard to urinary dysfunctions, crude analyses demonstrated that DPC was shorter (SDM, -1.369; 95% CI, -1.865 to -0.873), and urinary frequency and abnormal sensation were less common in NSRS (OR, 0.347 and 0.067; 95% CI, 0.183 to 0.658 and 0.013 to 0.340, respectively) ([Fig. 3](#F3){ref-type="fig"}). However, there were no significant differences in urinary incontinence, urinary retention, dysuria, and urinary urgency between CRS and NSRS ([Supplementary Fig. 3](#S3){ref-type="supplementary-material"}). In terms of anorectal dysfunctions, there were no significant differences in constipation, diarrhea, and fecal incontinence between the two treatments. Furthermore, a decrease in sexual interest, dyspareunia, a decrease in orgasm, or sexual satisfaction, and vaginal dryness were not significantly different between CRS and NSRS ([Supplementary Fig. 4](#S4){ref-type="supplementary-material"}).

In subgroup analyses based on study design, quality of study, surgical approach, radicality, postvoid residual urine volume not requiring DPC, follow-up for evaluating dysfunctions, and adjustment for potential confounding factors, DPC was still shorter, and urinary incontinence and urinary frequency were less common in NSRS. Furthermore, constipation was less frequent in NSRS after adjustment for age, adjuvant treatment, extent of lymphadenectomy, and FIGO stage (OR, 0.177; 95% CI, 0.078 to 0.401) ([Table 3](#T3){ref-type="table"}). However, there were no significant differences in sexual dysfunctions between CRS and NSRS ([Supplementary Table 5](#S9){ref-type="supplementary-material"}).

DISCUSSION
==========

Recent RCTs and one systematic review with a meta-analysis have reported the advantages of NSRS \[[@B11],[@B14]\]. However, they have some limitations as follows: small numbers of studies with low quality of RCTs: seven studies (41.2%) published in the Chinese literature in the systematic review with a metaanalysis, which can act as a bias to interpret meta-analytic results because of difficulty in accessing full papers and the disadvantage that most of the relevant studies have been performed in the limited area \[[@B11],[@B36],[@B37],[@B38],[@B39],[@B40],[@B41]\]; a lack of relevant studies comparing prognosis, anorectal or sexual dysfunctions between the two treatments. Although this meta-analysis could not also overcome these limitations completely, it has major advantages as follows: (1) inclusion of the largest number of relevant English literature which enabled us to compare most of the surgery-related issues between CRS and NSRS; (2) definition of the pelvic autonomic nerves which should be spared in NSRS in spite of different techniques; (3) comparison of urinary, anorectal, and sexual dysfunctions between the two treatments in terms of long-term outcomes (6 or 12 months after surgery); (4) subgroup analyses based on study design, quality of study, surgical approach, radicality, and adjustment for potential confounding factors in order to minimize bias.

As a result, we found that operative time was longer, and intraoperative complications were less common in NSRS despite no significant differences in blood loss, hospital stay, and postoperative complications. Longer operative time and less frequent intraoperative complications may result from more care taken to avoid damaging the pelvic nerves during NSRS. Thus, the surgical field can be dissected even wider than CRS, and meticulous and precise dissection can contribute to decreases in blood loss and injury to adjacent organs \[[@B12],[@B42]\].

Secondly, the length of the resected vagina was shorter in NSRS, while the length of the resected parametrium, DFS, and OS were not significantly different between CRS and NSRS. These finding can be supported by some studies suggesting that the level of colpectomy should be restricted to 2 cm in order to preserve the most distal portion of the vesical branch of the pelvic plexus \[[@B16],[@B24],[@B43]\]. On the other hand, the safety of NSRS still remains controversial because of the concerns of less radicality of NSRS \[[@B44],[@B45]\]. Although this meta-analysis was performed under the conditions that radicality could affect prognosis (up to 90% of patients with a large tumor of \>4 cm, and less than 50% of them who received adjuvant radiotherapy), it demonstrated that NSRS may not reduce the radicality affecting prognosis.

Thirdly, DPC was shorter, and urinary incontinence and frequency were less common in NSRS. Sympathetic nerves in the hypogastric nerve and the vesical branch of the pelvic plexus stimulate the urethral sphincter and inhibit the detrusor muscle of the bladder, whereas parasympathetic nerves in the pelvic splanchnic nerve and the vesical branch of the pelvic plexus relax the urethral sphincter and stimulate the detrusor muscle of the bladder \[[@B10],[@B46]\]. Thus, CRS may increase DPC, and urinary incontinence and frequency can be expected by autonomic dysregulation after surgical disruption \[[@B21],[@B22],[@B47],[@B48]\]. Thus, these meta-analyses is meaningful in supporting the efficacy of autonomic nerve preservation by NSRS on urinary functions.

Fourthly, constipation was less common in NSRS. Sympathetic nerves inhibit the expulsion of feces and stimulate the internal sphincter of the anus, whereas parasympathetic nerves show opposite effects \[[@B10],[@B46]\]. In particular, a previous study has suggested the hypothesis that injury to the pelvic autonomic nerves by CRS disrupts the spinal reflex, which causes internal sphincter dysregulation and decreased rectal sensation \[[@B6]\]. Thus, this meta-analysis supports the hypothesis and suggests that NSRS may reduce the incidence of functional defecation disorders, such as constipation.

Fifthly, there were no significant differences in sexual dysfunctions between CRS and NSRS. Theoretically, autonomic nerve fibers in the vascular smooth muscle cells of the vagina innervate reproductive organs and are responsive to circulating steroids \[[@B49]\]. Thus, damage to autonomic nerves caused by CRS may change the neurogenic control of the blood vessels of the vagina wall and thereby disturbs vaginal blood flow during sexual arousal and lubrication-swelling response \[[@B9],[@B49],[@B50],[@B51]\]. However, this meta-analysis failed to show a decrease in sexual dysfunctions by NSRS in comparison with CRS, which means that autonomic nerve preservation may not be associated with the improvement in sexual functions and that multiple factors, including vaginal shortness, tissue fibrosis, radiotherapy, a decrease in ovarian function, and psychological factors, may be more important to improve sexual functions \[[@B30]\].

When we consider that the nerve-sparing technique is not currently uniform, and thereby a large-scale RCT is not easy to perform, this meta-analysis is important because it showed the possibility that NSRS can give better quality of life by preserving urinary and anorectal functions without adverse effects on clinical outcomes and sexual functions in patients with early-stage cervical cancer. Furthermore, it is helpful in planning large-scale prospective randomized trials for valuable epidemiologic evidence.
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SUPPLEMENTARY MATERIALS
=======================

###### Supplementary Fig. 1

Funnel plots with Egger\'s test representing no publication bias in this meta-analysis for comparing clinical outcomes: (A) operative time, (B) blood loss, (C) hospital stay, (D) intraoperative complications, (E) postoperative complications, (F) disease-free survival, (G) overall survival, (H) duration of postoperative catheterization, (I) urinary incontinence, (J) urinary retention, (K) urinary frequency, (L) constipation, (M) decrease in sexual interest, and (N) dyspareunia between conventional and nerve-sparing radical surgery for cervical cancer.

###### Supplementary Fig. 2

Forest plots for standard differences (Std diffs) in means or odds ratios with 95% confidence intervals (CIs) to compare (A) operative time, (B) postoperative complications, (C) the length of the resected parametrium, (D) disease-free survival, and (E) overall survival between conventional radical surgery (CRS) and nerve-sparing radical surgery (NSRS) for cervical cancer.

###### Supplementary Fig. 3

Forest plots for standard differences (Std diffs) in means or odds ratios with 95% confidence intervals (CIs) to compare (A) urinary incontinence, (B) urinary retention, (C) dysuria, and (D) urinary urgency between conventional radical surgery (CRS) and nerve-sparing radical surgery (NSRS) for cervical cancer.

###### Supplementary Fig. 4

Forest plots for odds ratios with 95% confidence intervals (CIs) to compare (A) constipation, (B) diarrhea, (C) fecal incontinence, (D) a decrease in sexual interest, (E) dyspareunia, (F) decrease in orgasm, (G) decrease in sexual satisfaction, and (H) vaginal dryness between conventional radical surgery (CRS) and nerve-sparing radical surgery (NSRS) for cervical cancer.

###### Assessment of nerve sparing radical surgery for cervical cancer

![](jgo-26-100-s005)

  Study                                       Sites of nerve preservation   Success rate (%)                  
  ------------------------------------------- ----------------------------- ------------------ ------- ------ ------
  Possover et al. (2000) \[[@B16]\]           △                             O                  △       △      △
  Trimbos et al. (2001) \[[@B7]\]             O                             O                  O       △      △
  Querleu et al. (2002) \[[@B21]\]            O^\*^                         O^\*^              O^\*^   △      △
  Todo et al. (2006) \[[@B22]\]               O                             O                  O       0      100
  Raspagliesi et al. (2006) \[[@B10]\]        O^†^                          O^†^               O^†^    △      △
  Pieterse et al. (2008) \[[@B9]\]            O                             O                  O       △      △
  Van den Tillaart et al. (2009) \[[@B17]\]   O                             O                  O       19.7   80.3
  Cibula et al. (2010) \[[@B23]\]             O^‡^                          O^‡^               O^‡^    △      △
  Espino-Strebel et al. (2010) \[[@B24]\]     O                             O                  O       △      △
  Liang et al. (2010) \[[@B25]\]              O                             O                  O       △      △
  Skret-Magierlo et al. (2010) \[[@B18]\]     O                             O                  O       0      100
  Wu et al. (2010) \[[@B12]\]                 O                             O                  O       △      △
  Cibula et al. (2011) \[[@B26]\]             O                             O                  O       △      △
  Ditto et al. (2011) \[[@B27]\]              O                             O                  O       △      △
  Ceccaroni et al. (2012) \[[@B28]\]          O                             O                  O       △      △
  Chen et al. (2012) \[[@B13]\]               O                             O                  O       △      △
  Tseng et al. (2012) \[[@B19]\]              O                             O                  O       5.6    94.4
  Pieterse et al. (2013) \[[@B29]\]           O                             O                  O       0      100
  Bogani et al. (2014) \[[@B20]\]             O                             O                  O       △      △
  Wang et al. (2014) \[[@B30]\]               O                             O                  O       △      △

△ not mentioned. ^\*^27.1% of patients who received nerve sparing surgery underwent radical trachelectomy. ^†^6.8% of patients who underwent nerve sparing radical hysterectomy received neoadjuvant chemotherapy. ^‡^7.1% and 14.1% of all patients underwent radical parametrectomy and trachelectomy, respectively.

###### The Newcastle-Ottawa Scale for assessing qualities of 19 included cohort studies

![](jgo-26-100-s006)

  Study                                       Selection (score)   Comparability (score)   Outcome(score)   Total score                   
  ------------------------------------------- ------------------- ----------------------- ---------------- ------------- --- --- --- --- ---
  Possover et al. (2000) \[[@B16]\]           1                   1                       1                1             1   1   1   0   9
  Trimbos et al. (2001) \[[@B7]\]             0                   0                       1                1             1   1   0   0   4
  Querleu et al. (2002) \[[@B21]\]            1                   1                       1                0             1   1   1   1   7
  Todo et al. (2006) \[[@B22]\]               1                   0                       1                1             2   1   1   1   8
  Raspagliesi et al. (2006) \[[@B10]\]        1                   1                       1                0             2   1   1   0   7
  Pieterse et al. (2008) \[[@B9]\]            0                   0                       1                1             1   1   1   0   5
  Van den Tillaart et al. (2009) \[[@B17]\]   1                   1                       1                1             2   1   1   1   9
  Cibula et al. (2010) \[[@B23]\]             1                   0                       1                0             2   1   1   1   7
  Espino-Strebel et al. (2010) \[[@B24]\]     1                   1                       1                1             1   1   1   1   8
  Liang et al. (2010) \[[@B25]\]              1                   1                       1                1             2   1   1   1   9
  Skret-Magierlo et al. (2010) \[[@B18]\]     0                   0                       1                1             2   1   1   1   7
  Cibula et al. (2011) \[[@B26]\]             0                   0                       1                1             0   1   1   1   5
  Ditto et al. (2011) \[[@B27]\]              1                   1                       1                0             2   1   1   1   8
  Ceccaroni et al. (2012) \[[@B28]\]          1                   1                       1                1             2   1   1   1   9
  Tseng et al. (2012) \[[@B19]\]              0                   0                       1                1             2   1   1   1   7
  Pieterse et al. (2013) \[[@B29]\]           1                   1                       1                1             2   1   1   1   9
  Bogani et al. (2014) \[[@B20]\]             1                   1                       1                1             2   1   1   1   9
  Wang et al. (2014) \[[@B30]\]               1                   1                       1                1             2   1   1   1   9

###### Demographic characteristics of 20 included studies

![](jgo-26-100-s007)

  Study                                       Period of enrollment   Study design    FIGO stage      Surgical approach or type           Radicality   Sample size              Adjustment of potential confounding factors   
  ------------------------------------------- ---------------------- --------------- --------------- ----------------------------------- ------------ ------------------------ --------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Possover et al. (2000) \[[@B16]\]           1996-                  Prospective     IB2-IIA         LPS RH                              III          28                       38                                            Length of resected parametrium
  Trimbos et al. (2001) \[[@B7]\]             2000                   Prospective     Not mentioned   LPT RH                              III          2                        8                                             Age, adjuvant treatment, BMI, histology, NAC, tumor size
  Querleu et al. (2002) \[[@B21]\]            1991-1995^\*^          Retrospective   IA2-II          LPS RH or RT                        II           47                       48 (RT, n=13)                                 Extent of lymphadenectomy, FIGO stage, LNM, LVSI, no. of resected LNs, parametrial invasion, positive resection margin, tumor size
  1996-^†^                                                                                                                                                                                                                   
  Todo et al. (2006) \[[@B22]\]               2000-2002              Retrospective   IB1-IIB         LPT RH                              III          5                        22                                            Age, adjuvant treatment, extent of lymphadenectomy, FIGO stage, length of resected vagina, tumor size
  Raspagliesi et al. (2006) \[[@B10]\]        Not mentioned          Retrospective   IB1-III         LPT RH                              III          20                       59 (NAC, n=4)                                 Age, BMI, extent of lymphadenectomy, FIGO stage, grade, histology, LVSI, parametrial invasion, parity, positive resection margin, tumor size
  Pieterse et al. (2008) \[[@B9]\]            2006                   Prospective     I-IIA           LPT RH                              III          13                       10                                            Adjuvant treatment, menopause
  Van den Tillaart et al. (2009) \[[@B17]\]   1994-1999^\*^          Prospective     I-IIA           LPT RH                              III          124                      122                                           Age, adjuvant treatment, depth of stromal invasion, extent of lymphadenectomy, FIGO stage, histology, LNM, LVSI, parametrial invasion, positive resection margin, tumor size
  2001-2005^†^                                                                                                                                                                                                               
  Cibula et al. (2010) \[[@B23]\]             2006-2008              Retrospective   IA2-IIB         LPT RH or RP (7.1%) or RT (14.1%)   C            19                       35                                            Age, adjuvant treatment, BMI, extent of lymphadenectomy, no. of resected LNs, tumor size
  Espino-Strebel et al. (2010) \[[@B24]\]     2002-2007              Retrospective   IB1             LPT RH                              C            52                       27                                            Extent of lymphadenectomy, depth of stromal invasion, parametrial invasion, positive resection margin, tumor size
  Liang et al. (2010) \[[@B25]\]              2006-2009              Retrospective   IA2-IB2         LPS RH                              C            81                       82                                            Age, BMI, extent of lymphadenectomy, FIGO stage, histology, length of resected parametrium, length of resected vagina, no. of resected LNs, tumor size
  Skret-Magierlo et al. (2010) \[[@B18]\]     2007-2008              Prospective     IB1-IIA         LPT RH                              III          10                       10                                            Age, adjuvant treatment, BMI, extent of lymphadenectomy, FIGO stage. histology, LVSI, no. of resected LNs, tumor size
  Wu et al. (2010) \[[@B11]\]                 2007-2008              RCT             IB1-IIA         LPT RH                              III          15                       14                                            Age, adjuvant chemotherapy or radiotherapy, body mass index, extent of lymphadenectomy, FIGO stage, histology, LVSI, lymph node metastasis
  Cibula et al. (2011) \[[@B26]\]             2003-2007              Retrospective   IA-IIB          LPT RH, RP (6.3%) or RT (4.7%)      B or C       17^‡^                    175^§^                                        \-
  Ditto et al. (2011) \[[@B27]\]              1980-1995^\*^          Retrospective   IA2-IIB         LPT RH                              III          311 (NAC, n=56)          185 (NAC, n=162)                              Age, depth of stromal invasion, extent of lymphadenectomy, FIGO stage, histology, LNM, LVSI, parametrial invasion, positive resection margin
  2001-2009^†^                                                                                                                                                                                                               
  Ceccaroni et al. (2012) \[[@B28]\]          1997-2009              Retrospective   IA2-IIB         LPS or LPT RH                       III          31 (NAC, n=3)            25 (NAC, n=4)                                 Age, adjuvant treatment, extent of lymphadenectomy, FIGO stage, grade, histology, NAC, no. of resected LNs, surgical approach
  Chen et al. (2012) \[[@B13]\]               2007-2008              RCT             IB1-IIA         LPT RH                              III          13                       12                                            Age, adjuvant treatment, BMI, FIGO stage, LNM, positive resection margin
  Tseng et al. (2012) \[[@B19]\]              2010-2011              Prospective     IA2-IB1         LPT RH                              C            12                       18                                            Age, extent of lymphadenectomy, histology, LNM, parametrial invasion, positive resection margin, tumor size
  Pieterse et al. (2013) \[[@B29]\]           1998-2008              Retrospective   IA-IIB          LPT RH                              III          106 (\>stage IIB, n=1)   123                                           Age, adjuvant treatment, FIGO stage, hormone replacement therapy, menopause
  Bogani et al. (2014) \[[@B20]\]             2004-2012              Prospective     IA-IIB          LPS RH                              II or III    63 (NAC, n=12)           33 (NAC, n=7)                                 Age, adjuvant treatment, BMI, extent of lymphadenectomy, FIGO stage, grade, histology, length of resected parametrium, length of resected vagina, LNM, NAC
  Wang et al. (2014) \[[@B30]\]               2008-2012              Retrospective   IB1-IIA         LPT RH                              III          160 (NAC, n=42)          78 (NAC, n=25)                                Age, adjuvant treatment, BMI, depth of stromal invasion, extent of lymphadenectomy, FIGO stage, histology, LNM, NAC, ovarian transposition, parametrial invasion, positive resection margin

BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node; LNM, lymph node metastasis; LPS, laparoscopy; LPT, laparotomy; LVSI, lymphovascular space invasion; NAC, neoadjuvant chemotherapy; RCT, randomized controlled trial; RH, radical hysterectomy; RP, radical parametrectomy; RT, radical trachelectomy.

^\*^Conventional radical surgery was performed. ^†^Nerve sparing radical surgery was performed. ^‡^Type C2 radical surgery was performed. ^§^Type B or C1 radical surgery was performed.

###### Subgroup analyses for comparing clinical outcomes between conventional and nerve sparing radical surgery for cervical cancer
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  Category                                            No. of studies   SDM or OR   95% CI            Heterogeneity   Model used   
  --------------------------------------------------- ---------------- ----------- ----------------- --------------- ------------ ----------------
  Blood loss (SDM)                                                                                                                
   Study design                                                                                                                   
    RCT                                               2                -0.405      -0.945 to 0.135   0.605           \<0.001      Fixed effect
    Prospective                                       3                -0.022      -0.235 to 0.191   0.960           \<0.001      Fixed effect
    Retrospective                                     5                -0.374      -0.683 to 0.066   0.068           54.220       Random effects
   Quality of study (NOS)                                                                                                         
    ≥8                                                5                -0.332      -0.656 to 0.009   0.006           72.541       Random effects
    \<8                                               3                -0.018      -0.383 to 0.347   0.954           \<0.001      Fixed effect
   Surgical approach                                                                                                              
    Laparotomy                                        7                -0.093      -0.271 to 0.085   0.842           \<0.001      Fixed effect
    Laparoscopy                                       2                -0.395      -1.014 to 0.224   0.019           81.924       Random effects
   Radicality                                                                                                                     
    Type III or C                                     9                -0.297      -0.536 to 0.057   0.041           50.258       Random effects
   Adjustment for potential confounding factors                                                                                   
    Age, BMI, FIGO stage                              5                -0.339      -0.655 to 0.024   0.103           48.091       Fixed effect
    Age, BMI, extent of lymphadenetomy, FIGO stage    4                -0.346      -0.717 to 0.024   0.056           60.430       Fixed effect
  Hospital stay (SDM)                                                                                                             
   Study design                                                                                                                   
    Prospective                                       2                -0.096      -0.476 to 0.284   0.725           \<0.001      Fixed effect
    Retrospective                                     4                -0.259      -0.459 to 0.060   0.676           \<0.001      Fixed effect
   Quality of study (NOS)                                                                                                         
    ≥8                                                3                -0.244      -0.449 to 0.039   0.446           \<0.001      Fixed effect
    \<8                                               3                -0.166      -0.512 to 0.180   0.798           \<0.001      Fixed effect
   Surgical approach, and type                                                                                                    
    Laparotomy, and type III or C                     5                -0.258      -0.453 to 0.064   0.822           \<0.001      Fixed effect
   Adjustment for potential confounding factors                                                                                   
    Age, BMI, extent of lymphadenetomy, FIGO stage    4                -0.233      -0.436 to 0.030   0.574           \<0.001      Fixed effect
  Postoperative complications (OR)                                                                                                
   Study design                                                                                                                   
    Prospective                                       3                0.452       0.269 to 0.761    0.473           \<0.001      Fixed effect
    Retrospective                                     5                1.157       0.715 to 1.874    0.860           \<0.001      Fixed effect
   Quality of study (NOS)                                                                                                         
    ≥8                                                4                0.684       0.460 to 1.016    0.155           42.800       Fixed effect
    \<8                                               4                1.082       0.492 to 2.380    0.353           8.005        Fixed effect
   Radicality                                                                                                                     
    Type III or C                                     7                0.696       0.482 to 1.005    0.288           18.594       Fixed effect
   Adjustment for potential confounding factors                                                                                   
    Age, BMI, extent of lymphadenectomy, FIGO stage   4                0.868       0.496 to 1.522    0.543           \<0.001      Fixed effect

BMI, body mass index; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; NOS, the Newcastle-Ottawa Scale; OR, odds ratio; RCT, randomized controlled trial; SDM, standard difference in mean.

###### Subgroup analyses for comparing postoperative sexual functions between conventional and nerve sparing radical surgery for cervical cancer
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  Category                                                           No. of studies   OR      95% CI        Heterogeneity   Model used   
  ------------------------------------------------------------------ ---------------- ------- ------------- --------------- ------------ ----------------
  Decrease of sexual interest                                                                                                            
   Study design                                                                                                                          
    Prospective                                                      2                0.305   0.043-2.170   0.055           72.839       Random effects
    Retrospective                                                    3                0.774   0.467-1.281   0.461           \<0.001      Fixed effect
   Quality of study (NOS)                                                                                                                
    ≥ 8                                                              4                0.480   0.194-1.185   0.011           73.057       Random effects
   Surgical approach                                                                                                                     
    Laparotomy                                                       3                0.911   0.532-1.560   0.967           \<0.001      Fixed effect
   Radicality                                                                                                                            
    Type III or C                                                    4                0.786   0.484-1.277   0.659           \<0.001      Fixed effect
   Follow-up for evaluating dysfunctions (mo)                                                                                            
    12                                                               4                0.440   0.166-1.166   0.020           69.574       Random effects
   Adjustment for potential confounding factors                                                                                          
    Age, adjuvant treatment, FIGO stage                              4                0.480   0.194-1.185   0.011           73.057       Random effects
    Age, adjuvant treatment, extent of lymphadenectomy, FIGO stage   3                0.378   0.112-1.269   0.017           75.327       Random effects
  Dyspareunia                                                                                                                            
   Surgical approach                                                                                                                     
    Laparotomy                                                       2                0.763   0.408-1.426   0.449           \<0.001      Fixed effect
   Radicality                                                                                                                            
    Type III or C                                                    2                0.711   0.389-1.298   0.530           \<0.001      Fixed effect
   Follow-up for evaluating dysfunctions (mo)                                                                                            
    12                                                               2                0.504   0.223-1.138   0.754           \<0.001      Fixed effect
   Adjustment for potential confounding factors                                                                                          
    Age, adjuvant treatment, extent of lymphadenectomy, FIGO stage   3                0.759   0.350-1.648   0.467           75.327       Fixed effect

CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; NOS, the Newcastle-Ottawa Scale; OR, odds ratio.

![PRISMA diagram. The search strategy and number of studies identified for inclusion in this meta-analysis.](jgo-26-100-g001){#F1}

![Forest plots for standard differences (Std diffs) in means or odds ratios with 95% confidence intervals (CIs) to compare (A) blood loss, (B) hospital stay, (C) intraoperative complications, and (D) the length of the resected vagina between conventional radical surgery (CRS) and nerve-sparing radical surgery (NSRS) for cervical cancer.](jgo-26-100-g002){#F2}

![Forest plots for standard differences (Std diffs) in means or odds ratios with 95% confidence intervals (CIs) to compare (A) the duration of postoperative catheterization, (B) urinary frequency between conventional radical surgery (CRS) and nerve-sparing radical surgery (NSRS) for cervical cancer.](jgo-26-100-g003){#F3}

###### Subgroup analyses for comparing clinical outcomes between conventional and nerve sparing radical surgery for cervical cancer
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  Category                                                                 No. of studies   SDM or OR   95% CI            Heterogeneity   Model used   
  ------------------------------------------------------------------------ ---------------- ----------- ----------------- --------------- ------------ ----------------
  Operative time^\*^                                                                                                                                   
   Study design                                                                                                                                        
    RCT                                                                    2                0.263       -0.834 to 1.360   0.046           74.987       Random effects
    Prospective                                                            4                -0.691      -1.809 to 0.426   \<0.001         93.027       Random effects
    Retrospective                                                          6                0.253       -0.141 to 0.647   \<0.001         81.160       Random effects
   Quality of study (NOS)                                                                                                                              
    ≥8                                                                     6                -0.186      -1.088 to 0.717   \<0.001         97.305       Random effects
    \<8                                                                    4                0.086       -0.574 to 0.747   0.024           65.709       Random effects
   Surgical approach                                                                                                                                   
    Laparotomy                                                             9                -0.141      -0.861 to 0.579   \<0.001         94.381       Random effects
    Laparoscopy                                                            2                0.174       -1.364 to 1.711   \<0.001         96.935       Random effects
   Radicality                                                                                                                                          
    Type III or C                                                          11               0.328       -0.635 to 0.652   \<0.001         94.333       Random effects
   Adjustment for potential confounding factors                                                                                                        
    Age, BMI, FIGO stage                                                   7                0.253       -0.255 to 0.735   \<0.001         85.516       Random effects
    Age, BMI, extent of lymphadenetomy, FIGO stage,                        6                0.275       -0.380 to 0.697   \<0.001         88.314       Random effects
    Age, BMI, extent of lymphadenectomy, FIGO stage, no. of resected LNs   2                0.948       0.642 to 1.253    0.942           \<0.001      Fixed effect
  Intraoperative complications^†^                                                                                                                      
   Adjustment for potential confounding factors                                                                                                        
    Age, extent of lymphadenectomy, FIGO stage, no. of resected LNs        2                0.147       0.035 to 0.621    0.588           \<0.001      Fixed effect

BMI, body mass index; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; LNs, lymph nodes; NOS, the Newcastle-Ottawa Scale; RCT, randomized controlled trial.

^\*^SDM, standard difference in mean; ^†^OR, odds ratio.

###### Subgroup analyses for comparing survival between conventional and nerve sparing radical surgery for cervical cancer
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  Category                                                                No. of studies   HR      95% CI        Heterogeneity   Model used   
  ----------------------------------------------------------------------- ---------------- ------- ------------- --------------- ------------ ----------------
  Disease-free survival                                                                                                                       
   Study design, and quality of study (NOS)                                                                                                   
    Prospective and NOS=8                                                 3                1.026   0.673-1.565   0.468           \<0.001      Fixed effect
   Surgical approach                                                                                                                          
    Laparotomy                                                            3                1.038   0.666-1.618   0.403           \<0.001      Fixed effect
   Radicality                                                                                                                                 
    Type III or C                                                         2                1.003   0.635-1.585   0.228           31.146       Fixed effect
   Adjustment for potential confounding factors                                                                                               
    Age, adjuvant treatment, extent of lymphadenectomy, FIGO stage, LNM   2                1.453   0.691-3.054   0.598           \<0.001      Fixed effect
  Overall survival                                                                                                                            
   Study design, and quality of study (NOS)                                                                                                   
    Prospective, and NOS=8                                                3                1.075   0.433-2.611   0.054           65.805       Random effects
   Surgical approach                                                                                                                          
    Laparotomy                                                            3                1.124   0.422-2.944   0.044           68.098       Random effects
   Radicality                                                                                                                                 
    Type III or C                                                         3                0.862   0.324-2.293   0.095           57.436       Random effects
   Adjustment for potential confounding factors                                                                                               
    Age, adjuvant treatment, extent of lymphadenectomy, FIGO stage, LNM   2                1.680   0.862-3.274   0.774           \<0.001      Fixed effect

CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; LNM, lymph node metastasis; NOS, the Newcastle-Ottawa Scale.

###### Subgroup analyses for comparing postoperative urinary and anorectal functions between conventional and nerve sparing radical surgery for cervical cancer
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  Category                                                                                              No. of studies   SDM or OR   95% CI             Heterogeneity   Model used   
  ----------------------------------------------------------------------------------------------------- ---------------- ----------- ------------------ --------------- ------------ ----------------
  DPC^\*^                                                                                                                                                                            
   Study design                                                                                                                                                                      
    RCT                                                                                                 2                -1.907      -2.600 to -1.214   \<0.001         93.268       Random effects
    Prospective                                                                                         4                -2.167      -3.524 to -0.810   \<0.001         92.750       Random effects
    Retrospective                                                                                       6                -0.813      -1.330 to -0.296   \<0.001         89.152       Random effects
   Quality of study (NOS)                                                                                                                                                            
    ≥8                                                                                                  6                -1.002      -1.495 to -0.508   \<0.001         88.011       Random effects
    \<8                                                                                                 4                -1.874      -3.331 to -0.418   \<0.001         93.695       Random effects
   Surgical approach                                                                                                                                                                 
    Laparotomy                                                                                          7                -1.958      -2.914 to -1.003   \<0.001         93.118       Random effects
    Laparoscopy                                                                                         4                -0.978      -1.586 to -0.370   \<0.001         87.814       Random effects
   Radicality                                                                                                                                                                        
    Type III or C                                                                                       10               -1.622      -2.236 to -1.007   \<0.001         91.472       Random effects
   Postvoid residual urine not requiring DPC (mL)                                                                                                                                    
    \<50                                                                                                6                -2.178      -3.243 to -1.113   \<0.001         93.632       Random effects
    \<100                                                                                               5                -0.616      -0.805 to -0.428   0.001           77.275       Random effects
   Adjustment for potential confounding factors                                                                                                                                      
    Age, extent of lymphadenectomy, FIGO stage                                                          6                -0.982      -1.510 to -0.454   \<0.001         86.496       Random effects
    Age, extent of lymphadenectomy, FIGO stage, no. of resected LNs                                     2                -1.653      -1.989 to -1.318   0.786           \<0.001      Fixed effect
  Urinary incontinence^†^                                                                                                                                                            
   Study design                                                                                                                                                                      
    Prospective                                                                                         3                0.325       0.023 to 4.634     0.041           68.702       Random effects
    Retrospective                                                                                       5                0.592       0.403 to 0.869     0.103           48.005       Fixed effect
   Quality of study (NOS)                                                                                                                                                            
    ≥8                                                                                                  4                0.519       0.242 to 1.117     0.105           51.099       Random effects
    \<8                                                                                                 3                0.750       0.121 to 4.639     0.057           65.199       Random effects
   Radicality                                                                                                                                                                        
    Type III or C                                                                                       7                0.509       0.230 to 1.128     0.050           52.390       Random effects
   Follow-up for evaluating dysfunctions (mo)                                                                                                                                        
    6                                                                                                   2                0.214       0.018 to 2.507     0.090           65.272       Random effects
    12                                                                                                  6                0.743       0.273 to 2.025     0.072           50.492       Random effects
   Adjustment for potential confounding factors                                                                                                                                      
    Age, adjuvant treatment, FIGO stage                                                                 5                0.539       0.361 to 0.803     0.159           39.262       Fixed effect
    Age, adjuvant treatment, extent of lymphadenectomy, FIGO stage                                      4                0.489       0.288 to 0.830     0.098           52.298       Random effects
  Urinary frequency^†^                                                                                                                                                               
   Surgical approach, radicality, and adjustment for potential confounding factors                                                                                                   
    Laparotomy, and type III or C, and age, adjuvant treatment, extent of lymphadenectomy, FIGO stage   2                0.269       0.914 to 0.568     0.342           \<0.001      Fixed effect
  Urinary retention^†^                                                                                                                                                               
   Follow-up for evaluating dysfunctions (mo)                                                                                                                                        
    6                                                                                                   2                0.143       0.006 to 3.183     0.039           76.601       Random effects
   Quality of study (NOS), and adjustment for potential confounding factors                                                                                                          
    ≥8, and age, adjuvant treatment, extent of lymphadenectomy, FIGO stage                              2                0.301       0.051 to 1.762     0.173           46.252       Fixed effect
  Constipation^†^                                                                                                                                                                    
   Study design                                                                                                                                                                      
    Prospective                                                                                         2                0.648       0.153 to 2.749     0.491           \<0.001      Fixed effect
    Retrospective                                                                                       3                0.353       0.088 to 1.420     0.005           81.351       Random effects
   Quality of study (NOS)                                                                                                                                                            
    ≥8                                                                                                  4                0.343       0.102 to 1.159     0.012           72.430       Random effects
   Surgical approach                                                                                                                                                                 
    Laparotomy                                                                                          3                0.457       0.106 to 1.965     0.005           81.459       Random effects
   Radicality                                                                                                                                                                        
    Type III or C                                                                                       4                0.426       0.140 to 1.292     0.011           73.119       Random effects
   Follow-up for evaluating dysfunctions (mo)                                                                                                                                        
    12                                                                                                  4                0.765       0.426 to 1.371     0.519           \<0.001      Fixed effect
   Adjustment for potential confounding factors                                                                                                                                      
    Age, adjuvant treatment, FIGO stage                                                                 4                0.343       0.102 to 1.159     0.012           72.430       Random effects
    Age, adjuvant treatment, extent of lymphadenectomy, FIGO stage                                      3                0.177       0.078 to 0.401     0.509           \<0.001      Fixed effect

CI, confidence interval; DPC, duration of postoperative catheterization; FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node; NOS, the Newcastle-Ottawa Scale; RCT, randomized controlled trial.

^\*^SDM, standard difference in mean; ^†^OR, odds ratio.
